Cardiovascular

Educational resources

Index image

Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care

Commissioned by Amgen Ltd

This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only. 
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2416 March 2022

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2415 January 2022

Index image

Management of venous thromboembolism in primary care

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022

On-demand index image2

The impact of DOACs on stroke in patients with NVAF: practical considerations for those with comorbidities

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

These promotional videos have been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.   The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100966 | Date of preparation: January 2022